On September 22, drug notification delivery information published on the official website of the State Drug Administration showed that Tonghua Anruite Biopharmaceutical Co., Ltd.'s recombinant human albumin injection was issued a notice on September 21. This information was interpreted by the outside world as an unapproved domestic marketing application for this product. On September 24, the reporter called the 4 public landlines on Tonghua Anruite's official website, but none of them were answered; its wholly-owned subsidiary, Beijing Zhihe Xinchuang Biotechnology Co., Ltd., told the reporter every time that the outside world's interpretation was wrong. Issuing a notice did not mean that the product could not be approved, but the more specific situation needed to be further understood from Tonghua Anruite. As of press release, there has been no response to every interview email sent by the reporter to Tonghua Anrit's official website.

On September 22, drug notification delivery information published on the official website of the State Drug Administration showed that Tonghua Anruite Biopharmaceutical Co., Ltd.'s recombinant human albumin injection was issued a notice on September 21. This information was interpreted by the outside world as an unapproved domestic marketing application for this product. On September 24, the reporter called the 4 public landlines on Tonghua Anruite's official website, but none of them were answered; its wholly-owned subsidiary, Beijing Zhihe Xinchuang Biotechnology Co., Ltd., told the reporter every time that the outside world's interpretation was wrong. Issuing a notice did not mean that the product could not be approved, but the more specific situation needed to be further understood from Tonghua Anruite. As of press release, there has been no response to every interview email sent by the reporter to Tonghua Anrit's official website.